J&J earnings set ‘negative tone’; Shkreli vs. the FTC
BioPharma DiveBen FidlerOctober 14, 2026
A 6% sell-off in J J shares was viewed by one analyst as emblematic of broader market volatility. Elsewhere, Gilead is collaborating with Vir and a biotech s bid for a product expansion fell short.